$40.34
1.08% yesterday
NYSE, May 20, 10:00 pm CET
ISIN
US03770N1019
Symbol
APGE
Sector
Industry

Apogee Therapeutics Stock price

$40.34
+7.49 22.80% 1M
-4.70 10.44% 6M
-4.96 10.95% YTD
-12.08 23.04% 1Y
+19.11 90.01% 3Y
+19.11 90.01% 5Y
+19.11 90.01% 10Y
NYSE, Closing price Tue, May 20 2025
+0.43 1.08%
ISIN
US03770N1019
Symbol
APGE
Sector
Industry

Key metrics

Market capitalization $2.40b
Enterprise Value $1.90b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 3.57
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-241.79m
Free Cash Flow (TTM) Free Cash Flow $-193.13m
Cash position $513.33m
EPS (TTM) EPS $-3.54
P/E forward negative
Short interest 37.83%
Show more

Is Apogee Therapeutics a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Apogee Therapeutics Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Apogee Therapeutics forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Apogee Therapeutics forecast:

Buy
100%

Financial data from Apogee Therapeutics

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs 0.37 0.37
1,133% 1,133%
-
-0.37 -0.37
1,133% 1,133%
-
- Selling and Administrative Expenses 56 56
87% 87%
-
- Research and Development Expense 185 185
109% 109%
-
-241 -241
104% 104%
-
- Depreciation and Amortization 0.37 0.37
1,133% 1,133%
-
EBIT (Operating Income) EBIT -242 -242
104% 104%
-
Net Profit -205 -205
98% 98%
-

In millions USD.

Don't miss a Thing! We will send you all news about Apogee Therapeutics directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Apogee Therapeutics Stock News

Positive
Seeking Alpha
8 days ago
Apogee Therapeutics, Inc. achieved positive interim results from phase 1b study using APG808 for the treatment of patients with Asthma. Interim 16-week data from the phase 2 APEX study using APG777 for the treatment of patients with AD expected mid-2025. The global asthma treatment market size is projected to reach $35.93 billion by 2034.
Neutral
GlobeNewsWire
9 days ago
Phase 2 APEX trial of APG777 in atopic dermatitis advancing with interim Part A 16-week data expected in mid-2025 and Part B actively enrolling
Neutral
GlobeNewsWire
9 days ago
Multiple doses of APG808 resulted in rapid suppression of FeNO, a biomarker of Type 2 inflammation associated with exacerbations in asthma, with a robust maximal FeNO decrease from baseline of 53%
More Apogee Therapeutics News

Company Profile

Apogee Therapeutics, Inc. operates as a biotechnology company. It offers treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD) and related inflammatory and immunology (I&I) indications. The company was founded in February 2022 and is headquartered in Waltham, MA.

Head office United States
CEO Michael Henderson
Employees 196
Founded 2022
Website www.apogeetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today